Brazilian Dialysis Survey 2023.

IF 1.3 Q3 UROLOGY & NEPHROLOGY
Fabiana B Nerbass, Helbert do Nascimento Lima, Jorge P Strogoff-de-Matos, Bruno Zawadzki, José A Moura-Neto, Jocemir Ronaldo Lugon, Ricardo Sesso
{"title":"Brazilian Dialysis Survey 2023.","authors":"Fabiana B Nerbass, Helbert do Nascimento Lima, Jorge P Strogoff-de-Matos, Bruno Zawadzki, José A Moura-Neto, Jocemir Ronaldo Lugon, Ricardo Sesso","doi":"10.1590/2175-8239-JBN-2024-0081en","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The annual Brazilian Dialysis Survey (BDS) supports and contributes to the development of national health policies. Objective: To report the 2023 epidemiological data from the BDS of the Brazilian Society of Nephrology (BSN).</p><p><strong>Methods: </strong>A survey was carried out in a voluntary sample of Brazilian chronic dialysis centers using an online questionnaire covering clinical and epidemiological aspects of patients on chronic dialysis, and characteristics of dialysis centers. For estimates of prevalence, incidence, and source of payment for dialysis, data were obtained from a random sample of dialysis centers.</p><p><strong>Results: </strong>A total of 37.5% (n = 332) of the centers voluntarily responded to the online questionnaire, and 124 were randomly selected for specific estimates of prevalence and incidence rates. It was estimated that on July 1, 2023, the total number of patients on dialysis was 157,357 and 51,153 started dialysis in 2023. The estimated prevalence and incidence rates of patients per million population (pmp) were 771 and 251, respectively. Of the prevalent patients, 88.2% were on hemodialysis, 8.0% on hemodialfiltration, and 3.8% on peritoneal dialysis. The prevalence of anemia (Hb <10g/dL) was 29% and hyperphosphatemia (P >5.5mg/dL), 30%. There was an increase in the frequency of use of cinacalcet and paricalcitol. The estimated overall crude annual mortality rate was 16.2%.</p><p><strong>Conclusions: </strong>Estimates from a random sample of dialysis facilities show that the absolute number and the prevalence rate of patients on chronic dialysis continue to increase. A growing number of patients were undergoing hemodiafiltration and using cinacalcet and paricalcitol for hyperparathyroidism treatment.</p>","PeriodicalId":14724,"journal":{"name":"Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia","volume":"47 1","pages":"e20240081"},"PeriodicalIF":1.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801593/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/2175-8239-JBN-2024-0081en","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The annual Brazilian Dialysis Survey (BDS) supports and contributes to the development of national health policies. Objective: To report the 2023 epidemiological data from the BDS of the Brazilian Society of Nephrology (BSN).

Methods: A survey was carried out in a voluntary sample of Brazilian chronic dialysis centers using an online questionnaire covering clinical and epidemiological aspects of patients on chronic dialysis, and characteristics of dialysis centers. For estimates of prevalence, incidence, and source of payment for dialysis, data were obtained from a random sample of dialysis centers.

Results: A total of 37.5% (n = 332) of the centers voluntarily responded to the online questionnaire, and 124 were randomly selected for specific estimates of prevalence and incidence rates. It was estimated that on July 1, 2023, the total number of patients on dialysis was 157,357 and 51,153 started dialysis in 2023. The estimated prevalence and incidence rates of patients per million population (pmp) were 771 and 251, respectively. Of the prevalent patients, 88.2% were on hemodialysis, 8.0% on hemodialfiltration, and 3.8% on peritoneal dialysis. The prevalence of anemia (Hb <10g/dL) was 29% and hyperphosphatemia (P >5.5mg/dL), 30%. There was an increase in the frequency of use of cinacalcet and paricalcitol. The estimated overall crude annual mortality rate was 16.2%.

Conclusions: Estimates from a random sample of dialysis facilities show that the absolute number and the prevalence rate of patients on chronic dialysis continue to increase. A growing number of patients were undergoing hemodiafiltration and using cinacalcet and paricalcitol for hyperparathyroidism treatment.

巴西透析调查2023。
巴西年度透析调查(BDS)支持并促进国家卫生政策的制定。目的:报告巴西肾病学会(BSN) BDS的2023年流行病学数据。方法:在巴西慢性透析中心的自愿样本中进行调查,使用在线问卷调查慢性透析患者的临床和流行病学方面以及透析中心的特点。为了估计透析的患病率、发病率和支付来源,数据来自透析中心的随机样本。结果:共有37.5% (n = 332)的中心自愿回答了在线问卷,并随机选择124个中心进行患病率和发病率的具体估计。据估计,截至2023年7月1日,透析患者总数为157357人,2023年开始透析的患者为51153人。每百万人口(pmp)的估计患病率和发病率分别为771例和251例。88.2%的患者接受血液透析,8.0%接受血液透析滤过,3.8%接受腹膜透析。贫血患病率(Hb 5.5mg/dL), 30%。cinacalcet和paricalcitol的使用频率有所增加。估计总粗年死亡率为16.2%。结论:对透析设施随机抽样的估计表明,慢性透析患者的绝对数量和患病率继续增加。越来越多的患者正在进行血液滤过并使用cinacalcet和paricalcitol治疗甲状旁腺功能亢进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.20
自引率
16.70%
发文量
208
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信